NIH R01 · 2024
PROJECT SUMMARY A safe, effective, affordable and acceptable vaccine against HIV has been an epidemic-ending goal for decades, and recent years have seen substantial progress towards developing and testing promising candidate vaccines. For highly vulnerable groups like adolescent girls and young women (AGYW) in sub-Saharan Africa, access and uptake of vaccines will be essential for reducing the exceptionally high HIV incidence observed in recent years. This is particularly true in South Africa, which has the world's largest HIV epidemic and several active HIV vaccine trial programs. While an HIV vaccine has the potential to substantially reduce HIV risk, realizing this potential will…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.